avatar

Auto-generated profile, based on publicly available information


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
HLHye Yoon Lee
Hye Yoon Lee
YCYoung Woo Chang
Young Woo Chang
DYDa Young Yu
Da Young Yu
TLTae-Yul Lee
Tae-Yul Lee
DKDuk Woo Kim
Duk Woo Kim
GSGil Soo Son
Gil Soo Son
Lee HY, et al. J Breast Cancer. 2021 Apr;24(2):196-205. https://doi.org/10.4048/jbc.2021.24.e18

1 February 2002 in Surgery Today
Verified
Journal Article
Closed access
PDF file
JLJae Bok Lee
Jae Bok Lee
KRKeun Won Ryu
Keun Won Ryu
TSTae-Jin Song
Tae-Jin Song
SSSung Ock Suh
Sung Ock Suh
YKYoung Chul Kim
Young Chul Kim
SCSang Yong Choi
Sang Yong Choi

1 January 2025 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JKJi Hye Kim
Ji Hye Kim
YKYong Yeup Kim
Yong Yeup Kim
JCJai Hyun Chung
Jai Hyun Chung
WKWoo Young Kim
Woo Young Kim
JLJae Bok Lee
Jae Bok Lee
SWSang-Uk Woo
Sang-Uk Woo
Kim JH, et al. J Breast Cancer. 2025 Feb;28:e8. https://doi.org/10.4048/jbc.2024.0190

31 January 2022 in The Breast Journal
Verified
Journal Article
Open access
PDF file
YKYong Yeup Kim
Yong Yeup Kim
HKHayeon Kim
Hayeon Kim
WKWoo Young Kim
Woo Young Kim
JCJai Hyun Chung
Jai Hyun Chung
JLJae Bok Lee
Jae Bok Lee
SWSang-Uk Woo
Sang-Uk Woo
Purpose. Phyllodes tumors (PTs) of the breast are rare fibroepithelial neoplasms, and factors associated with the recurrence of PTs are poorly understood. This study sought to identify clinicopathological factors associated with the recurrence of PTs. Method. From January 2009 to December 2019, we identified 100 patients who underwent definitive surgery for PT. Clinicopathological risk factors associated with the recurrence of PT were assessed. Results. The median age of the patients was 44 y (range, 19–62 y), and the median tumor size was 4 cm (0.8–30 cm). At a median follow-up of 26.7 mo (0–103 mo), 22 of the 100 patients experienced local recurrence. In the univariate and multivariate analyses, body mass index ≥ 23 kg/m2 ( = 0.042 in the univariate analysis; = 0.039 in the multivariate analysis), tumor size ≥ 5 cm ( = 0.006 in the univariate analysis; = 0.036 in the multivariate analysis), and the presence of stromal overgrowth ( = 0.032 in the univariate analysis; = 0.040 in the multivariate analysis) were associated with an increased risk of local recurrence. Resection margins and grade were not associated with local recurrence. Conclusion. Normal- or underweight patients and those with larger tumor sizes were more prone to local recurrence. Further larger, multicenter studies with a long-term follow-up are required.

1 January 2026 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
JKJi Hye Kim
Ji Hye Kim
YKYeryung Kim
Yeryung Kim
JCJai Hyun Chung
Jai Hyun Chung
YKYong Yeup Kim
Yong Yeup Kim
WKWoo Young Kim
Woo Young Kim
SWSang-Uk Woo
Sang-Uk Woo
While progesterone receptor (PR) negativity in luminal-type breast cancer is generally associated with worse oncologic outcomes, its prognostic role in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer remains underexplored. This study aimed to evaluate the prognostic significance of PR expression in ER-positive, HER2-positive breast cancer. A retrospective analysis was conducted on patients diagnosed with ER-positive, HER2-positive breast cancer who underwent primary surgery at Korea University Guro Hospital between January 2009 and December 2019. Patients were grouped by PR expression as negative/low (Allred score, 0–6) or strongly positive (Allred score,7 or 8). Prognostic outcomes, including disease-free survival (DFS), distant recurrence-free survival (DRFS), and breast cancer-specific survival (BCSS) were analyzed. A total of 223 patients were included. Patients in the negative/low PR group were older compared to the strongly positive PR group. The negative/low PR group showed significantly worse DFS (P = 0.005) and DRFS (P = 0.014) but showed no significant difference in BCSS (P = 0.153). On multivariate analysis, negative or low PR expressions were linked to inferior DFS (hazard ratio [HR], 3.10; 95% confidence interval [CI], 1.34–7.16; P = 0.008) and DRFS (HR, 9.55; 95% CI, 1.22–74.77; P = 0.032). In ER-positive, HER2-positive breast cancer, negative or weak PR expression was associated with inferior DFS and DRFS compared to strong PR expression. These findings highlight the potential prognostic value of PR status in this group, underscoring its relevance in guiding treatment and follow-up strategies for more individualized patient care.

1 January 2024 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
JKJi Hye Kim
Ji Hye Kim
YKYong Yeup Kim
Yong Yeup Kim
JCJai Hyun Chung
Jai Hyun Chung
WKWoo Young Kim
Woo Young Kim
JLJae Bok Lee
Jae Bok Lee
SWSang-Uk Woo
Sang-Uk Woo
Kim JH, et al. Ann Surg Treat Res. 2024 Apr;106(4):189-194. https://doi.org/10.4174/astr.2024.106.4.189